Table 1 Trials characteristics
Number | Percent | |
|---|---|---|
Trial phase | ||
Phase I/II | 48 | 17.3 |
Phase II | 200 | 72.2 |
Phase II/III | 4 | 1.4 |
Phase III | 25 | 9.0 |
Sponsor | ||
NIH | 33 | 11.9 |
Industry | 60 | 21.7 |
Other | 184 | 66.4 |
Enrollment size | ||
0–50 | 136 | 49.1 |
51–100 | 65 | 23.5 |
101–200 | 40 | 14.4 |
201–300 | 6 | 2.2 |
301-more | 16 | 5.8 |
NR | 14 | 5.1 |
Number of centers | ||
1 | 97 | 35.0 |
2 | 6 | 2.2 |
multicenter | 174 | 62.8 |
Number of arms | ||
1 | 196 | 70.8 |
2 | 67 | 24.2 |
≥3 | 14 | 5.1 |
Treatment allocation | ||
Non-randomized | 209 | 75.5 |
Randomized | 68 | 24.5 |
Masking | ||
Open-label | 257 | 6.9 |
Single-blind | 1 | 0.4 |
Double-blind | 19 | 92.8 |
Region | ||
United states | 186 | 67.1 |
Europe | 65 | 23.5 |
Asia | 26 | 9.4 |